Carbonic Anhydrases III and IV Autoantibodies in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Diabetes, Hypertensive Renal Disease, and Heart Failure
Table 1
The anti-CA III, IV titers, and the CA activity of subjects (mean (SD)).
RA
SLE
T1D
T1DN
T2D
T2DN
HTN
HT
anti-CA III (abs)
control
0.058 (0.015)
0.056 (0.021)
0.064 (0.015)
0.041 (0.009)
0.053 (0.012)
0.064 (0.013)
0.049 (0.010)
0.061 (0.012)
patients
0.195* (0.079)
0.327* (0.644)
0.073 (0.022)
0.204* (0.083)
0.065 (0.023)
0.056 (0.019)
0.096 (0.057)
0.065 (0.025)
positive
11.2%
14.8%
0.0%
6.7%
0.0%
0.0%
0.0%
0.0%
anti-CA IV (abs)
control
0.021 (0.013)
0.032 (0.013)
0.027 (0.006)
0.019 (0.007)
0.026 (0.009)
0.027 (0.011)
0.035 (0.012)
0.026 (0.009)
patients
0.183* (0.063)
0.205* (0.688)
0.033 (0.013)
0.022* (0.105)
0.022 (0.006)
0.049 (0.018)
0.028 (0.011)
0.131* (0.045)
positive
9.8%
10.6%
0.0%
4.2%
0.0%
0.0%
0.0%
5.3%
CA activity (EU/mL)†
control
8.65 (2.86)
7.96 (3.12)
8.12 (2.57)
8.56 (2.13)
8.63 (2.64)
8.47 (2.32)
7.98 (3.65)
8.12 (2.43)
patients
10.37* (4.36)
12.48* (5.68)
8.66 (4.36)
13.07* (5.58)
9.32 (3.97)
12.65* (4.56)
9.65* (4.51)
13.47* (5.08)
*There were significant differences between patients and control (P < 0.05). †n = 10 (5 males and 5 females). HTN: hypertensive nephropathy; HT: heart failure.
